ArticleOrphanet journal of rare diseases2026

Real-world safety assessment of burosumab: a pharmacovigilance study utilizing the FDA adverse event reporting system.

Tingting Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.